Post-myocardial infarction β-blocker therapy: The bradycardia conundrum. Rationale and design for the Pacemaker & β-blocker therapy post-MI (PACE-MI) trial

American Heart Journal

Volumn 155, Issue 3, 2008, Pages 455-464

  Goldberger, Jeffrey J ^a   Bonow, Robert O ^a   Cuffe, Michael ^b   Dyer, Alan ^c   Greenland, Philip ^c   Rosenberg, Yves ^d   O'Rourke, Robert ^e   Shah, Prediman K ^f   Smith, Sidney ^g  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DUKE UNIVERSITY HEALTH SYSTEM   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL; METOPROLOL SUCCINATE;

ARTICLE; ARTIFICIAL HEART PACEMAKER; BRADYCARDIA; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG EFFECT; HEART INFARCTION; HEART REINFARCTION; HUMAN; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; BRADYCARDIA; CARDIAC PACING, ARTIFICIAL; HEART RATE; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 39249083147     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.10.041     Document Type: Article

References (82)

1. The DAVID Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator. The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 288 (2002) 3115-3123
2. Beta-Blocker Heart Attack Study Group. A randomized trial of propranolol in patients with acute myocardial infarction I. Mortality results. JAMA 247 (1982) 1707-1714
3. Hansteen V., Moinichen E., Lorentsen E., et al. One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian Multicentre Trial. Br Med J (Clin Res Ed) 284 (1982) 155-160
4. Hjalmarson A., Herlitz J., Malek I., et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomized trial. Lancet 2 (1981) 823-827
5. Pedersen T. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. N Engl J Med 313 (1985) 1055-1058
6. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304 (1981) 801-807
7. Teo K., Yusuf S., and Furberg C. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 270 (1993) 1589-1595
8. Freemantle N., Cleland J., Young P., et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 318 (1999) 1730-1737
9. Cucherat M., Boissel J.P., and Leizorovicz A. Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. The APSI Investigators. Acebutolol et Prevention Secondaire de l'Infarctus. Am J Cardiol 79 (1997) 87-589
10. Krumholz H., Radford M., Wang Y., et al. National use and effectiveness of β-blockers for the treatment of elderly patients after acute myocardial infarction: national cooperative cardiovascular project. JAMA 280 (1998) 623-629
11. Gottlieb S., McCarter R., and Vogel R. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 339 (1998) 489-497
12. Soumerai S., McLaughlin T., Spiegelman D., et al. Adverse outcomes of underuse of b-blockers in elderly survivors of acute myocardial infarction. JAMA 277 (1997) 115-121
13. Pfisterer M., Cox J., Granger C., et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 32 (1998) 634-640
14. Aronow W., and Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and systemic hypertension treated with beta blockers, angiotensin-converting enzyme inhibitors, diuretics, calcium antagonists, and alpha blockers. Am J Cardiol 89 (2002) 1207-1209
15. Aronow W., Ahn C., and Kronzon I. Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am J Cardiol 88 (2001) 1298-1300
16. O'Rourke R. Beta-adrenergic blocking agents or angiotensin converting enzyme inhibitors, or both, for postinfarction patients with left ventricular dysfunction. J Am Coll Cardiol 29 (1997) 237-239
17. Spargias K., Hall A., Greenwood D., et al. Beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study. Heart 81 (1999) 25-32
18. Vantrimpont P., Rouleau J., Wun C., et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the survival and ventricular enlargement (SAVE) study. J Am Coll Cardiol 29 (1997) 229-236
19. Chen J., Radford M., Wang Y., et al. Are beta-blockers effective in elderly patients who undergo coronary revascularization after acute myocardial infarction?. Arch Intern Med 160 (2000) 947-952
20. Kernis S., Harjai K., Stone G., et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty?. J Am Coll Cardiol 43 (2004) 1773-1779
21. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357 (2001) 1385-1390
22. Antman E., Anbe D., Armstrong P., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines on the Management of Patients with Acute Myocardial Infarction). Circulation 110 (2004) 588-636
23. Braunwald E, Antman E, Beasley J, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). 2002. Available at http://www.acc.org/clinical/guidelines/unstable/unstable.pdf.
24. Ryan T., Antman E., Brooks N., et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on management of acute myocardial infarction). Circulation 100 (1999) 1016-1030
25. Krumholz H.M., J A., Brooks N.H., et al. ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-Elevation Myocardial Infarction). Circulation 113 (2006) 732-761
26. Frishman W., Furberg C., and Friedewald W. Beta-adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med 310 (1984) 830-837
27. Olsson G., Wikstrand J., Warnold I., et al. Metoprolol-induced reduction in mortality: pooled results from five double-blind randomized trials. Eur Heart J 13 (1992) 28-32
28. Yusuf S., Peto R., Lewis J., et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27 (1985) 335-371
29. Kjekshus J. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 57 (1986) 43F-49F
30. Gundersen T., Grottum P., Pedersen T., et al. Effect of timolol on mortality and reinfarction after acute myocardial infarction: prognostic importance of heart rate at rest. Am J Cardiol 58 (1986) 20-24
31. Hjalmarson A., Gilpin E., Kjekshus J., et al. Influence of heart rate on mortality after myocardial infarction. Am J Cardiol 65 (1990) 547-553
32. Boden W., vanGilst W., Scheldewaert R., et al. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomized placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT). Lancet 355 (2000) 1751-1756
33. Hansen J., and for the Danish Study Group on Verapamilin Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II-DAVIT II). Am J Cardiol 66 (1990) 779-785
34. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 319 (1988) 385-392
35. Cairns J., Connolly S., Roberts R., et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 349 (1997) 675-682
36. Julian D., Camm A., Frangin G., et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 349 (1997) 667-674
37. Rathore S., Weinfurt K., Gersh B., et al. Treatment of patients with myocardial infarction who present with a paced rhythm. Ann Intern Med 134 (2001) 644-651
38. Lechat P., Hulot J., Escolano S., et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation 103 (2001) 1428-1433
39. Gullestad L., Wikstrand J., Deedwania P., et al. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker?. J Am Coll Cardiol 45 (2005) 252-259
40. Barron H., Viskin S., Lundstrom R., et al. Beta-blocker dosages and mortality after myocardial infarction: data from a large health maintenance organization. Arch Intern Med 158 (1998) 449-453
41. Rochon P., Tu J., Anderson G., et al. Rate of heart failure and 1-year survival for older people receiving low-dose beta-blocker therapy after myocardial infarction. Lancet 356 (2000) 639-644
42. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol 80 Suppl (1997) 35J-39J
43. Panidis I., and Morganroth J. Initiating events of sudden cardiac death. Cardiovasc Clin 15 (1985) 81-92
44. Anderson J., Rodier H., and Green L. Comparative effects of beta-adrenergic blocking drugs on experimental ventricular fibrillation threshold. Am J Cardiol 51 (1983) 1196-1202
45. Billman G., Castillo L., Hensley J., et al. Beta-2-adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence for enhanced sensitivity to beta-2-adrenergic stimulation in animals susceptible to sudden death. Circulation 96 (1997) 1914-1922
46. Exner D., Reiffel J., Epstein A., et al. Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the antiarrhythmics versus implantable defibrillators (AVID) trial. J Am Coll Cardiol 34 (1999) 325-333
47. Hallstrom A., Cobb L., Yu B., et al. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol 68 (1991) 1025-1031
48. Avanzini F., Zuanetti G., Latini R., et al. Use of beta-blocking agents in secondary prevention after myocardial infarction: a case for evidence-based medicine?. Eur Heart J 18 (1997) 1447-1456
49. Brand D., Newcomer L., Freiburger A., et al. Cardiologists' practices compared with practice guidelines: use of beta-blockage after acute myocardial infarction. J Am Coll Cardiol 26 (1995) 1432-1436
50. Chen J., Radford M., Wang Y., et al. Do "America's best hospitals" perform better for acute myocardial infarction. N Engl J Med 340 (1999) 286-292
51. Shahar E., Lewis M., Keil U., et al. Hospital care and survival of acute myocardial infarction patients in Minnesota and southern Germany: a comparative study. Coron Artery Dis 7 (1996) 467-473
52. Viskin S., Kitzis I., Lev E., et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol 25 (1995) 1327-1332
53. Barakat K., Wilkinson P., Deaner A., et al. How should age affect management of acute myocardial infarction? A prospective cohort study. Lancet 353 (1999) 955-959
54. Mahon N., Codd M., O'Rorke C., et al. Management and outcome of acute myocardial infarction in older patients in the thrombolytic era. J Am Geriatr Soc 47 (1999) 291-294
55. Mendelson G., and Aronow W. Underutilization of beta-blockers in older patients with prior myocardial infarction or coronary artery disease in an academic, hospital-based geriatrics practice. J Am Geriatr Soc 45 (1997) 1360-1361
56. The MIAMI Trial Research Group. Metroprolol in acute myocardial infarction (MIAMI): a randomized placebo-controlled international trial. Eur Heart J 6 (1985) 199-226
57. Roberts R., Roberts W., and Mueller H. Immediate versus deferred beta blockade following thrombolysis in myocardial infarction. Circulation 83 (1991) 422-437
58. Rogers W., Canto J., Lambrew C., et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999: the national registry of myocardial infarction 1, 2 and 3. J Am Coll Cardiol 36 (2000) 2056-2063
59. Venturini F., Romero M., and Tognoni G. Patterns of practice for acute myocardial infarction in a population from ten countries. Eur J Clin Pharmacol 54 (1999) 877-886
60. Heller D., Ahern F., and Kozak M. Changes in rates of beta-blocker use between 1994 and 1997 among elderly survivors of acute myocardial infarction. Am Heart J 140 (2000) 663-671
61. Fehrenbach S., Budnitz D., Gazmararian J., et al. Physician characteristics and the initiation of beta-adrenergic blocking agent therapy after acute myocardial infarction in a managed care population. Am J Manag Care 7 (2001) 717-723
62. Phillips K., Shlipak M., Coxson P., et al. Health and economic benefits of increased beta-blocker use following myocardial infarction. JAMA 284 (2000) 2748-2754
63. White H., Barbash G., Califf R., et al. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries Trial. Circulation 94 (1996) 1826-1833
64. Aronow W. Postinfarction use of beta-blockers in elderly patients. Drugs Aging 11 (1997) 424-432
65. The Norwegian Multicenter Study Group. Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction. Circulation 66 (1982) 1179-1184
66. Hoffman J., Grimm W., Menz V., et al. Heart rate variability and major arrhythmic events in patients with idiopathic dilated cardiomyopathy. Pacing Clin Electrophysiol 19 11 Pt 2 (1996) 1841-1844
67. Benchimol A., and Liggett M. Cardiac hemodynamics during stimulation of the right atrium, right ventricle, and left ventricle in normal and abnormal hearts. Circulation 33 (1966) 933-944
68. Bengtsson C., Johnsson G., and Regardh C. Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment. Clin Pharmacol Ther 17 (1975) 400-408
69. Riddell J., Harron D., and Shanks R. Comparative effects of adimolol, labetalol, and propranolol on heart rate and blood pressure in man. Br J Clin Pharmacol 19 (1985) 405-410
70. Thomas M., and Tattersfield A. Comparison of beta-adrenoceptor selectivity of acebutolol and its metabolite diacetolol with metoprolol and propranolol in normal man. Eur J Clin Pharmacol 29 (1986) 679-683
71. Berkowitz W., Wit A., Lau S., et al. The effects of propranolol on cardiac conduction. Circulation 40 (1969) 855-862
72. Smithen C., Balcon R., and Sowton E. Use of bundle of His potentials to assess changes in atrioventricular conduction produced by a series of beta-adrenergic blocking agents. Br Heart J 33 (1971) 955-961
73. Greenblatt D., and Koch-Weser J. Adverse reactions to propranolol in hospitalized medical patients: a report from the Boston Collaborative Drug Surveillance Program. Am Heart J 86 (1973) 478-484
74. Greenblatt D., and Koch-Weser J. Adverse reactions to beta-adrenergic receptor blocking drugs: a report from the Boston Collaborative Drug Surveillance Program. Drugs 7 (1974) 118-129
75. Fallen E., Cairns J., Dafoe W., et al. Management of the postmyocardial infarction patient: a consensus report-revision of 1991 CCS Guidelines. Can J Cardiol 11 (1995) 477-486
76. Gunnar R., Bourdillon P., Dixon D., et al. Guidelines for the early management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee to develop guidelines for the early management of patients with acute myocardial infarction). J Am Coll Cardiol 16 (1990) 249-292
77. Kiviniemi M., Irnes PM., Eranen H., et al. Complications related to permanent pacemaker therapy. Pacing Clin Electrophysiol 22 (1999) 711-720
78. Link M., Estes N., Griffin J., et al. Complications of dual chamber pacemaker implantation in the elderly. J Interv Card Electrophysiol 2 (1998) 175-179
79. Moss A., Zareba W., Hall W., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
80. Saad E., Marrouche N., Martin D., et al. Frequency and associations of symptomatic deterioration after dual-chamber defibrillator implantation in patients with ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 90 (2002) 79-82
81. Sharma A.D., Rizo-Patron C., Hallstrom A.P., et al. Percent right ventricular pacing predicts outcomes in the DAVID trial. Heart Rhythm 2 (2005) 830-834
82. Ozcan C., Janhangir A., Friedman P., et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 344 (2001) 1043-1051